A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
Public ClinicalTrials.gov record NCT07609914. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE 4, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF REDOSING OF RIMEGEPANT IN PARTICIPANTS 18 YEARS OF AGE OR OLDER FOR THE ACUTE TREATMENT OF MIGRAINE
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Acute treatments for migraine may not provide sufficient pain relief after an initial dose, and a second dose of a given medication may be needed to fully abort an attack. International Headache Society (IHS) global practice recommendations for the Acute Treatment of Migraine suggest a second dose of the same medication within the recommended dose limit in people with headache relapse after successful initial treatment of a migraine attack. The primary purpose of this study is to evaluate the safety and tolerability of redosing of rimegepant when taken for the acute treatment of a migraine attack, as it is possible that some patients may benefit from a second dose of rimegepant in this setting.
Study identification
- NCT ID
- NCT07609914
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 400 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 27, 2026
- Primary completion
- May 14, 2028
- Completion
- May 14, 2028
- Last update posted
- Aug 23, 2026
2026 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Hope Clinical Research | Canoga Park | California | 91303 | Recruiting |
| Clinical Research Institute | Los Angeles | California | 90048 | Recruiting |
| Neurology Offices of South Florida | Boca Raton | Florida | 33428 | Recruiting |
| Brainstorm Research | Miami | Florida | 33176 | Recruiting |
| Clinical Neuroscience Solutions | Orlando | Florida | 32801 | Recruiting |
| New England Regional Headache Center | Worcester | Massachusetts | 01609 | Recruiting |
| Michigan Headache & Neurological Institute | Ann Arbor | Michigan | 48104 | Recruiting |
| Proven Endpoints, LLC | Ridgeland | Mississippi | 39157 | Recruiting |
| Headache Wellness Center | Greensboro | North Carolina | 27405 | Recruiting |
| FutureSearch Trials of Neurology | Austin | Texas | 78731 | Recruiting |
| FutureSearch Trials of Dallas | Dallas | Texas | 75251 | Recruiting |
| Medstar Health - Department of Neurology | McLean | Virginia | 22101 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07609914, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 23, 2026 · Synced Sep 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07609914 live on ClinicalTrials.gov.